Prevention of Infectious Keratitis after Corneal Refractive Surgery
Received: 16-May-2016 / Accepted Date: 02-Jun-2016 / Published Date: 06-Jun-2016 DOI: 10.4172/2476-2075.1000117
Corneal infections are, although not frequent, a major concern after laser in situ keratomileusis (LASIK) and surface ablation (SA) techniques (PRK, LASEK and epi-LASIK).
The real prevalence of infectious keratitis after refractive surgery is difficult to determine, due to its rarity. In 2010 we reported a prevalence of 72 cases in 204,586 LASIK procedures, a 0.035% . Other series had shown prevalences ranging from 0.034 to 0.180% [1-6], but ours was, by far, the largest series published to date. As happens in LASIK, the prevalence of infections after SA is rare and it is difficult to determine if the series does not comprise a large number of operated eyes. In 2011 we published our prevalence in SA . We found 39 cases in 18,651 procedures, a 0.200%. Therefore, in our institution, corneal infections were five times more prevalent after SA than after LASIK.
There is much consensus about the standard treatment of corneal infections after corneal refractive surgery. According to the ASCRS White Paper  aggressive management with early flap lifting, scraping, culture, and irrigation with antibiotics should be followed. When the infection has an early onset (less than 15 days) moxifloxacin 0.5% (or gatifloxacin 0.3%) is recommended along with cefazolin 50 mg/ml every 30 minutes. If it has a late onset (more than 15 days) moxifloxacin 0.5% (or gatifloxacin 0.3%) must be alternated with amikacin 35 mg/ml. In every case, oral doxicyclin is to be administered (100 mg, twice a day).
However, on the other hand, there is little consensus about the prophylactic preoperative treatment that should be implemented. It is common practice to use antibiotic eye drops after corneal refractive surgery to avoid this potentially severe complication. Our treatment regime was tobramycin 3 mg/ml, four times daily, for one week.
In 2010 moxifloxacin 5 mg/ml eye drops became available in our country. Clinica Baviera is a private institution with more than 20 centres and 70 ophthalmic surgeons throughout Spain, and more than 40,000 procedures are performed every year. At that time we changed our postoperative protocol and added moxifloxacin (fiur times daily for a week) to tobramycin, in order to reduce the rate of infectious keratitis.
Moxifloxacin is a fourth-generation fluoroquinolone. These antibiotics provide a broad range of coverage, both for gram positive and gram negative bacteria with low toxicity and good ocular penetration. They exhibit a great activity against gram positive bacteria, particularly S. pneumoniae, as well as anaerobic bacteria and nontuberculous mycobacteria. However, moxifloxacin can be less active against Pseudomonas aeruginosa than tobramycin. Thus, we opted to use the combination of moxifloxacin and tobramycin as our prophylactic treatment after corneal refractive surgery.
From November 2010 to December 2013 a total of 45,755 and 9,500 patients underwent respectively LASIK and SA with the new treatment regime, representing 91,340 LASIK procedures and 16,674 SA. Infectious keratitis was detected in 10 eyes of 9 patients (overall rate, 0.011% per procedure) within 6 months after LASIK and in 11 eyes of 10 patients after surface ablation (overall rate, 0.066% per procedure).
The incidence of post-LASIK infectious keratitis decreased when postoperative prophylaxis when the combination of tobramycin and moxifloxacin was implemented, from 0.035 to 0.011. After SA, the incidence lowered from 0.200 to 0.066. Thus, approximately one third of corneal infections appeared with the combination of both antibiotics. Infections after SA are still 6 times more frequent than after LASIK .
As a conclusion, these are the prophylactic measures that we highly recommend when performing LASIK or SA :
Preoperatively: cleaning eyelids and eyelashes 3 to 5 days before the operation.
Intraoperatively: applying povidone-iodine on the eyelids, using sterile and single-use material and carefully operating.
Postoperatively: moxifloxacin and tobramycin, four times a day, for one week.
In case of SA, trying not to use bandage contact lenses for too long.
- Llovet F, de Rojas V, Interlandi E, Martin C, Cobo-Soriano R, et al. (2010) Infectious keratitis in 204586 LASIK procedures. Ophthalmology 17:232-238.
- Lin RT, Maloney RK (1999) Flap complications associated with lamellar refractive surgery. Am J Ophthalmol 127: 129-136.
- Stulting RD, Carr JD, Thomppson KP, Waring GO 3rd, Wiley WM, et al. (1999) Complications of laser in situ keratomileusis for the correction of myopia. Ophthalmology 106: 13-20.
- Solomon R, Donnenfeld ED, Azar Dt, Holland EJ, Palmon FR, et al. (2003) Infectious keratitis after laser in siu keratomileusis: results of an ASCRS survey. J Cataract Refract Surg 29: 2001-2006.
- Moshirfar M, Welling JD, Feiz V, Holz H, Clinch TE (2007) Infectious and non-infectious keratitis after laser in situ keratomileusisOccurrence, management and visual outcomes. J Cataract Refract Surg 33: 474-483.
- Donnenfeld ED, Kim TK, Holland EJ, Azar DT, Palmon FR, et al. (2005)ASCRS White Paper: Management of infectious keratitis following laser in situ keratomileusis.. J Cataract Refract Surg 31:2008-2011.
- de Rojas V, Llovet F, Martínez M, Cobo-Soriano R, Ortega-Usobiaga J, et al. (2011) Infectious keratitis in 16851 laser surface ablation procedures. J Cataract Refract Surg 37:1822-1831.
- Ortega-Usobiaga J, Llovet-Osuna F, Djodeyre MR, Llovet-Rausell A, Beltrán J, et al. (2015) Incidence of corneal infections after laser in situ keratomileusis and surface ablation when moxifloxacin and tobramycin are used as postoperative treatment. J Cataract Refract Surg 41:1210-1216.
- Llovet Osuna F, Ortega-Usobiaga J (2014) Cirugía Refractiva: Protocolos [Refractive Surgery: Guidelines]. Madrid: Spanish Society of Ophthalmology(ISBN 978-84-89085-54-1).
Citation: Ortega-Usobiaga J, Llovet-Osuna F (2016) Prevention of Infectious Keratitis after Corneal Refractive Surgery. Optom Open Access 1: 117. Doi: 10.4172/2476-2075.1000117
Copyright: © 2016 Ortega-Usobiaga J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
8th International Conference on Eye and VisionParis, France
Open Access Journals
- Total views: 10205
- [From(publication date): 6-2016 - Mar 23, 2023]
- Breakdown by view type
- HTML page views: 9552
- PDF downloads: 653